Valuation: Newron Pharmaceuticals S.p.A.

Market Cap 257M 294M 238M 218M 413M 28.33B 420M 2.83B 1.11B 13.86B 1.1B 1.08B 47.74B P/E 2026 *
-9.1x
P/E 2027 * 33.4x
Enterprise Value 296M 338M 274M 251M 475M 32.59B 483M 3.26B 1.28B 15.95B 1.27B 1.24B 54.92B EV / Sales 2026 *
27.3x
EV / Sales 2027 * 6.06x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day-0.35%
1 week-3.38%
Current month-12.42%
1 month-5.62%
3 months-32.67%
6 months-54.86%
Current year-52.12%
1 week 11.34
Extreme 11.34
12.24
1 month 11.34
Extreme 11.34
13.18
Current year 11.34
Extreme 11.34
31.85
1 year 6.5
Extreme 6.5
31.85
3 years 4.09
Extreme 4.09
31.85
5 years 1.01
Extreme 1.01
31.85
10 years 0.9
Extreme 0.9
31.85
Manager TitleAgeSince
Chief Executive Officer 62 2012-05-14
Director of Finance/CFO - 2011-12-31
Chief Operating Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 62 2012-05-14
Director/Board Member - 2023-03-31
Director/Board Member - 2024-04-16
Date Insider Type Main position Quantity % Market Cap.
12/3/25 Sell 5,465 0.0274%
12/3/25 Fiscal year

Founder

5,465 0.0274%
11/27/25 Fiscal year

Founder

14,567 0.0730%
Change 5-day change 1-year change 3-year change Capi.($)
-0.35%-3.38%+60.62%+99.65% 296M
-1.07%+0.38%+2.06%+5.66% 50.35B
-2.85%-5.58%+373.90%+572.09% 39.21B
+1.78%+3.29%+33.49%-4.80% 34.52B
+1.98%+5.15%+17.69%+61.68% 34.6B
+0.06%-0.57%+3.35%+27.42% 27.05B
-3.27%-6.27% - - 16.68B
+1.64%+1.11%+72.02%+121.18% 15.11B
+0.29%+3.64%+15.30%+17.80% 13.85B
-1.21%+2.74%+16.77%-30.96% 13.18B
Average -0.30%+0.42%+66.13%+96.63% 24.49B
Weighted average by Cap. -0.31%+0.69%+79.60%+118.89%

Financials

2026 *2027 *
Net sales 10.84M 12.41M 10.03M 9.21M 17.42M 1.2B 17.73M 120M 46.89M 585M 46.58M 45.56M 2.01B 44.83M 51.31M 41.48M 38.07M 72.02M 4.94B 73.31M 495M 194M 2.42B 193M 188M 8.33B
Net income -31.17M -35.68M -28.84M -26.47M -50.08M -3.44B -50.98M -344M -135M -1.68B -134M -131M -5.79B 5.02M 5.75M 4.65M 4.27M 8.07M 554M 8.21M 55.41M 21.72M 271M 21.58M 21.11M 933M
Net Debt 38.68M 44.28M 35.79M 32.85M 62.14M 4.26B 63.26M 427M 167M 2.09B 166M 163M 7.19B 14.72M 16.84M 13.62M 12.5M 23.64M 1.62B 24.07M 162M 63.64M 794M 63.22M 61.84M 2.73B
Logo Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Employees
27
Date Price Change Volume
26-07-16 CHF 11.42 -0.35% 59,910
26-07-15 CHF 11.46 -1.04% 78,260
26-07-14 CHF 11.58 -1.36% 26,226
26-07-13 CHF 11.74 -0.51% 34,169
26-07-10 CHF 11.80 -1.99% 43,258
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.35EUR
Average target price
51.43EUR
Spread / Average Target
+316.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NWRN Stock